Article

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia

Department of Hematology and Internal Oncology, University of Leipzig, Leipzig, Germany.
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K (Impact Factor: 9.38). 06/2008; 22(8):1542-50. DOI: 10.1038/leu.2008.107
Source: PubMed

ABSTRACT Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well as unspecific immune reactions known as graft-versus-leukaemia (GvL) effects. Specific immune reactions are likely to be particularly relevant to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), in which residual cells may remain quiescent and unresponsive to cytotoxic and molecular therapies for long periods of time. Specific GvL effects result from the expression on leukaemic cells of specific tumour-associated antigens (TAAs) in the context of HLA proteins. As human leukocyte antigen (HLA) types vary widely, the development of broadly applicable tumour vaccines will require the identification of multiple TAAs active in different HLA backgrounds. Here, we describe the identification of NM23-H2 as a novel HLA-A32-restricted TAA of CML cells and demonstrate the presence of specifically reactive T cells in a patient 5 years after transplantation. As the NM23 proteins are aberrantly expressed in a range of different tumours, our findings suggest potential applications beyond CML and provide a new avenue of investigation into the molecular mechanisms underlying CML.

Download full-text

Full-text

Available from: Christoph Huber, Apr 10, 2014
1 Follower
 · 
115 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer now affects 1 in 3 people prompting an expansion in new and improved diagnostic techniques. Treatment modes include ways to boost the immune system, which is already adept at destroying infected tissues, and which may be guided to target cancerous cells. This is more commonly known as cancer immunotherapy and it has the potential to provide an effective targeted and personalised medicine for the elimination of cancer cells. We know that some specific proteins are expressed at very low levels in healthy cells but are overexpressed in cancer cells. Such differential expression can be studied in the laboratory (on the bench) and after much evidencing of their clinical utility may be used as therapy targets for cancer patients (at the bedside). To this end we describe how tumour antigens are researched in the literature (in silico) or identified and validated through broader (immuno-) screening programmes. We discuss how animal models are utilised to show the effect of targeting tumour antigens on the development of cancer. Finally we overview how the target antigen will need to stimulate the immune system in a way which best induces effective responses. This chapter overviews current practises with regards to antigen and peptide identification and the journey from bench to bedside.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer now affects 1 in 3 people prompting an expansion in new and improved diagnostic techniques. Treatment modes include ways to boost the immune system, which is already adept at destroying infected tissues, and which may be guided to target cancerous cells. This is more commonly known as cancer immunotherapy and it has the potential to provide an effective targeted and personalised medicine for the elimination of cancer cells. We know that some specific proteins are expressed at very low levels in healthy cells but are overexpressed in cancer cells. Such differential expression can be studied in the laboratory (on the bench) and after much evidencing of their clinical utility may be used as therapy targets for cancer patients (at the bedside). To this end we describe how tumour antigens are researched in the literature (in silico) or identified and validated through broader (immuno-) screening programmes. We discuss how animal models are utilised to show the effect of targeting tumour antigens on the development of cancer. Finally we overview how the target antigen will need to stimulate the immune system in a way which best induces effective responses. This chapter overviews current practises with regards to antigen and peptide identification and the journey from bench to bedside.
    Gene Therapy, 1 01/2013: chapter 12: pages 298-325; INTECH.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An elevated serum level of NM23-H1 protein is a poor prognostic factor in patients with various hematologic malignancies. The extracellular NM23-H1 protein promotes the in vitro growth and survival of acute myelogenous leukemia (AML) cells and inversely inhibits the in vitro survival of normal peripheral blood monocytes in primary culture at concentrations equivalent to the levels found in the serum of AML patients. The growth and survival promoting activity to AML cells is associated with cytokine production and activation of mitogen-activated protein kinases (MAPKs) and signal transducers and activators of transcription (STAT) signaling pathways. Inhibitors specific for MAPK signaling pathways inhibit the growth/survival-promoting activity of NM23-H1. These findings indicate a novel biological action of extracellular NM23-H1 and its association with poor prognosis. These results suggest an important role of extracellular NM23-H1 in the malignant progression of leukemia and a potential therapeutic target for these malignancies.
    Advances in Hematology 01/2012; 2012(1687-9104):879368. DOI:10.1155/2012/879368